In gemcitabine hcl nos 200mg
Products billed under this code include Gemcitabine.
Payment limit per 200 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Gemcitabine.
Payment limit per 200 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Gemcitabine | Hikma Pharmaceuticals USA Inc. | 00143-9340-01 | 1 | $2.734 |
| Gemcitabine | Hikma Pharmaceuticals USA Inc. | 00143-9341-01 | 5 | $13.67 |
| Gemcitabine | Hikma Pharmaceuticals USA Inc. | 00143-9342-01 | 10 | $27.34 |
| Gemcitabine | Pfizer Inc | 00409-0181-01 | 5 | $13.67 |
| Gemcitabine | Pfizer Inc | 00409-0181-25 | 5 | $13.67 |
| Gemcitabine | Pfizer Inc | 00409-0182-01 | 10 | $27.34 |
| Gemcitabine | Pfizer Inc | 00409-0182-25 | 10 | $27.34 |
| Gemcitabine | Pfizer Inc | 00409-0183-01 | 1 | $2.734 |
| Gemcitabine | Pfizer Inc | 00409-0183-25 | 1 | $2.734 |
| Gemcitabine | Pfizer Inc | 00409-0185-01 | 1 | $2.734 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Gemcitabine | Pfizer Inc | 00409-0186-01 | 5 | $13.67 |
| Gemcitabine | Pfizer Inc | 00409-0187-01 | 10 | $27.34 |
| Gemcitabine | Northstar RxLLC | 16714-0909-01 | 1 | $2.734 |
| Gemcitabine | Northstar RxLLC | 16714-0930-01 | 5 | $13.67 |
| Gemcitabine | Sagent Pharmaceuticals | 25021-0234-10 | 1 | $2.734 |
| Gemcitabine | Sagent Pharmaceuticals | 25021-0235-50 | 5 | $13.67 |
| Gemcitabine | Sagent Pharmaceuticals | 25021-0235-51 | 50 | $136.70 |
| Gemcitabine | Sagent Pharmaceuticals | 25021-0239-05 | 1 | $2.734 |
| Gemcitabine | Sagent Pharmaceuticals | 25021-0239-26 | 5 | $13.67 |
| Gemcitabine | Sagent Pharmaceuticals | 25021-0239-52 | 10 | $27.34 |
| Gemcitabine | FreseniUS Kabi USA, LLC | 63323-0102-13 | 1 | $2.734 |
| Gemcitabine | FreseniUS Kabi USA, LLC | 63323-0125-53 | 5 | $13.67 |
| Gemcitabine | Mylan Institutional LLC | 67457-0616-10 | 1 | $2.734 |
| Gemcitabine | Mylan Institutional LLC | 67457-0617-30 | 5 | $13.67 |
| Gemcitabine | Mylan Institutional LLC | 67457-0618-10 | 10 | $27.34 |
| Gemcitabine | Athenex Pharmaceutical Division, LLC | 70860-0205-50 | 5 | $13.67 |
| Gemcitabine | Meitheal Pharmaceuticals Inc. | 71288-0113-10 | 1 | $2.734 |
| Gemcitabine | Meitheal Pharmaceuticals Inc. | 71288-0114-50 | 5 | $13.67 |
| Gemcitabine | Meitheal Pharmaceuticals Inc. | 71288-0117-06 | 1 | $2.734 |
| Gemcitabine | Meitheal Pharmaceuticals Inc. | 71288-0117-28 | 5 | $13.67 |
| Gemcitabine | Meitheal Pharmaceuticals Inc. | 71288-0117-54 | 10 | $27.34 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2.734 | −$0.15 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted September 17, 2026 |
| 3Q26 | $2.884 | −$0.353 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted September 15, 2026 |
| 2Q26 | $3.237 | −$0.353 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted September 15, 2026 |
| 1Q26 | $3.59 | +$0.462 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted September 15, 2026 |
| 4Q25 | $3.128 | +$0.17 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted September 8, 2026 |
| 3Q25 | $2.958 | −$0.018 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted March 10, 2026 |
| 2Q25 | $2.976 | +$0.111 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted March 10, 2026 |
| 1Q25 | $2.865 | +$0.071 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted December 19, 2025 |
| 4Q24 | $2.794 | −$0.502 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 11, 2025 |
| 3Q24 | $3.296 | −$0.358 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 11, 2025 |
| 2Q24 | $3.654 | +$0.003 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted March 11, 2025 |
| 1Q24 | $3.651 | −$0.281 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted December 19, 2024 |
| 4Q23 | $3.932 | +$0.226 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted October 10, 2024 |
| 3Q23 | $3.706 | +$0.379 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 5, 2024 |
| 2Q23 | $3.327 | −$0.175 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted February 23, 2024 |
| 1Q23 | $3.502 | −$0.174 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted December 6, 2023 |
| 4Q22 | $3.676 | −$0.088 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 22, 2023 |
| 3Q22 | $3.764 | −$0.213 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 9, 2023 |
| 2Q22 | $3.977 | +$0.13 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted December 14, 2022 |
| 1Q22 | $3.847 | +$0.031 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 8, 2022 |
| 4Q21 | $3.816 | −$0.159 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 2, 2022 |
| 3Q21 | $3.975 | −$0.168 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted June 2, 2022 |
| 2Q21 | $4.143 | +$0.175 | 200 MG | In gemcitabine hcl nos 200mg | v1, posted March 1, 2022 |
| 1Q21 | $3.968 | – | 200 MG | In gemcitabine hcl nos 200mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.